Home ยป Lower-Dose CagriSema Delivers About 21% Weight Loss in REDEFINE 9 Trial

Lower-Dose CagriSema Delivers About 21% Weight Loss in REDEFINE 9 Trial

by Team SunilMadhavs World

1-Minute Summary

Lower doses of once-weekly cagrilintide plus semaglutide, the investigational fixed-dose combination known as CagriSema, produced substantial weight loss in adults with obesity or overweight without diabetes in the phase 3b REDEFINE 9 randomized clinical trial.

The trial enrolled 309 adults with a mean age of 48 years and mean BMI of 39.1 kg/mยฒ; 77% were women. Participants were randomly assigned in a 2:1:2:1 ratio to CagriSema containing 1.7 mg of cagrilintide plus 1.7 mg of semaglutide, corresponding placebo, 1.0 mg of each component, or corresponding placebo.

At 68 weeks, using the efficacy estimand, mean body weight decreased by 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with CagriSema 1.0 mg/1.0 mg, compared with 2.0% with pooled placebo.

The estimated treatment differences versus placebo were โˆ’18.8 percentage points for the 1.7-mg dose and โˆ’19.0 percentage points for the 1.0-mg dose; both comparisons were highly statistically significant at P < .0001.

More than 95% of participants receiving either CagriSema dose achieved at least 5% weight loss.

Adverse events were common but were predominantly gastrointestinal and mild to moderate in severity. Treatment discontinuation because of adverse events occurred in fewer than 5% of participants in each group, and no deaths occurred.

The findings suggest that clinically substantial weight reduction may be achievable with CagriSema doses below the 2.4-mg dose of each component studied most extensively in the broader development program.


Why This Matters

The development of incretin- and amylin-based therapies has substantially changed pharmacologic management of obesity.

CagriSema combines 2 complementary mechanisms:

Cagrilintide is a long-acting amylin analogue that may enhance satiety and reduce food intake.

Semaglutide is a glucagon-like peptide-1 receptor agonist that reduces appetite and energy intake while contributing to clinically meaningful weight reduction.

Much of the earlier phase 3 CagriSema program focused on a dose containing 2.4 mg of each drug. REDEFINE 9 addressed an important practical question: whether lower doses might retain substantial efficacy.

That question has implications for individualized obesity treatment. If lower doses produce large weight reductions, clinicians may eventually have greater flexibility to select doses according to treatment response, tolerability, and patient preference.

However, REDEFINE 9 was designed to compare each CagriSema dose with placeboโ€”not to establish whether the 1.0-mg dose is equivalent or superior to the 1.7-mg dose.


Study at a Glance

Feature Details
Study REDEFINE 9
Study type Multicentre, randomized, double-blind within dose level, placebo-controlled, parallel-group phase 3b trial
Participants 309 adults
Mean age 48 years
Women 77%
Mean BMI 39.1 kg/mยฒ
Population Adults with obesity or overweight plus โ‰ฅ1 obesity-related complication
Diabetes Participants with diabetes were excluded
Randomization 2:1:2:1
Intervention 1 Once-weekly cagrilintide 1.7 mg + semaglutide 1.7 mg
Intervention 2 Once-weekly cagrilintide 1.0 mg + semaglutide 1.0 mg
Comparator Corresponding placebo groups, pooled for analyses
Starting dose 0.25 mg of each component
Dose escalation 12 weeks for 1.7-mg regimen; 8 weeks for 1.0-mg regimen
Administration Once-weekly subcutaneous injection
Treatment period 68 weeks
Follow-up Through week 74
Coprimary outcome 1 Percentage change in body weight at week 68
Coprimary outcome 2 Proportion achieving โ‰ฅ5% body-weight reduction at week 68
Main finding Approximately 21% weight reduction with either CagriSema dose under the efficacy estimand
Funding Novo Nordisk

Trial Population

Eligible adults had either:

  • a BMI of at least 30 kg/mยฒ, or

  • a BMI of at least 27 kg/mยฒ plus at least 1 obesity-related complication.

Participants did not have diabetes.

The published study included:

Baseline characteristic Value
Randomized participants 309
Mean age 48.0 years
Mean BMI 39.1 kg/mยฒ
Women 77%
Men 23%

The treatment groups included 104 participants assigned to CagriSema 1.7 mg/1.7 mg, 103 assigned to CagriSema 1.0 mg/1.0 mg, and 102 assigned to pooled placebo.


Treatment and Dose Escalation

Participants receiving the higher-dose regimen started with cagrilintide 0.25 mg plus semaglutide 0.25 mg weekly and underwent dose escalation over 12 weeks before reaching the target dose of 1.7 mg of each component.

Those assigned to the 1.0-mg regimen underwent escalation over 8 weeks.

The source reported average weekly doses of approximately:

Assigned regimen Average weekly dose reported
CagriSema 1.7 mg/1.7 mg 1.3 mg of each component
CagriSema 1.0 mg/1.0 mg 0.8 mg of each component

Despite differences in assigned and average doses, the observed efficacy estimates at week 68 were remarkably similar.

Deborah B. Horn, DO, MPH, commented on this finding:

โ€œThat doesnโ€™t explain why we have the same efficacy. More for you and I to learn.โ€

The observation is hypothesis-generating rather than proof that the 2 doses are equivalent.


What the Researchers Found

Approximately 21% Weight Loss at 68 Weeks

Under the efficacy estimand, which estimates treatment effects assuming participants continued assigned treatment, mean body-weight reductions at week 68 were:

Week 68 outcome CagriSema 1.7 mg/1.7 mg CagriSema 1.0 mg/1.0 mg Pooled placebo
Mean body-weight change โˆ’20.7% โˆ’21.0% โˆ’2.0%
Standard error 0.9 1.0 1.0
Estimated difference vs placebo โˆ’18.8 percentage points โˆ’19.0 percentage points โ€”
95% CI โˆ’21.5 to โˆ’16.0 โˆ’21.8 to โˆ’16.2 โ€”
P value <.0001 <.0001 โ€”

Both CagriSema regimens therefore produced substantially greater weight reduction than placebo.

The numerical similarity between the 1.0-mg and 1.7-mg regimens should not be interpreted as evidence that the lower dose is superior or equivalent because the trial was not powered for a direct comparison between the 2 active-dose groups.


At Least 5% Weight Loss

The second coprimary endpoint was the proportion of participants achieving at least 5% body-weight reduction at week 68.

โ‰ฅ5% weight loss at week 68 Participants
CagriSema 1.7 mg/1.7 mg 95.1%
CagriSema 1.0 mg/1.0 mg 96.3%
Pooled placebo 33.4%

Compared with placebo, the estimated treatment difference was:

  • 61.7 percentage points for CagriSema 1.7 mg/1.7 mg

    • 95% CI, 49.5-74.0

    • P < .0001

  • 63.0 percentage points for CagriSema 1.0 mg/1.0 mg

    • 95% CI, 51.1-74.9

    • P < .0001

Thus, nearly all participants who remained on either CagriSema regimen under the efficacy estimand achieved clinically meaningful weight reduction.


Higher Weight-Loss Thresholds

Additional results from the published trial showed that large proportions of CagriSema-treated participants achieved progressively greater weight-loss thresholds.

Weight-loss threshold CagriSema 1.7 mg/1.7 mg CagriSema 1.0 mg/1.0 mg Placebo
โ‰ฅ5% 95.1% 96.3% 33.4%
โ‰ฅ10% 87.3% 86.0% 13.6%
โ‰ฅ15% 70.5% 70.7% 5.8%
โ‰ฅ20% 51.3% 48.3% 2.7%

These results indicate that approximately half of participants receiving either active regimen achieved weight loss of at least 20% under the efficacy estimand.


Treatment-Regimen Estimand

Results were somewhat more conservative when analyzed using the treatment-regimen estimand, which better reflects outcomes regardless of treatment discontinuation or other intercurrent events.

At week 68:

Outcome CagriSema 1.7 mg/1.7 mg CagriSema 1.0 mg/1.0 mg Placebo
Mean weight change โˆ’19.4% โˆ’18.6% โˆ’4.6%
โ‰ฅ5% weight loss 92.8% 87.7% 41.1%
โ‰ฅ10% weight loss 85.4% 78.7% 21.3%
โ‰ฅ15% weight loss 69.6% 63.4% 9.5%
โ‰ฅ20% weight loss 47.5% 44.7% 5.6%

The direction and magnitude of benefit remained substantial under this analysis.


Waist Circumference

The trial also demonstrated clinically meaningful reductions in waist circumference.

At week 68, reductions were approximately:

Treatment Waist-circumference reduction
CagriSema 1.7 mg/1.7 mg โˆ’17.2 cm
CagriSema 1.0 mg/1.0 mg โˆ’17.5 cm
Placebo โˆ’3.6 cm

Both comparisons with placebo were statistically significant.

These findings suggest that CagriSema treatment reduced not only total body weight but also central adiposity, an important marker of obesity-related metabolic risk.


Safety

Adverse events were common across all groups.

Safety outcome CagriSema 1.7 mg/1.7 mg CagriSema 1.0 mg/1.0 mg Placebo
Any adverse event 99% 95% 91%
Discontinued treatment because of adverse events 2.9% 4.9% 4.9%
Deaths 0 0 0

Most adverse events were gastrointestinal and mild to moderate in severity, consistent with the known adverse-effect profile of therapies acting through GLP-1 and amylin pathways.

Despite the high overall frequency of adverse-event reporting, treatment discontinuation because of adverse events remained relatively uncommon.


Why the Similar Efficacy of the 2 Doses Is Interesting

One of the more intriguing observations from REDEFINE 9 was the numerical similarity between the 1.0-mg and 1.7-mg regimens.

Under the efficacy estimand:

  • 1.7 mg/1.7 mg produced 20.7% weight loss.

  • 1.0 mg/1.0 mg produced 21.0% weight loss.

These results may suggest that the dose-response relationship for CagriSema is not strictly linear within this range.

However, several cautions are essential.

The study was not designed or statistically powered to establish equivalence between the 2 CagriSema doses.

Therefore, clinicians should not conclude that 1.0 mg is as effective as 1.7 mg solely because the point estimates were similar.

Further studies and dose-response analyses will be required to identify the optimal dose for individual patients.


Clinical Significance

REDEFINE 9 broadens the evidence base for CagriSema by demonstrating that doses lower than 2.4 mg of each component can produce substantial weight reduction.

This finding may ultimately have several clinical implications.

Potential for Dose Individualization

Obesity medications are increasingly used as long-term therapies.

A range of effective doses could allow clinicians to tailor treatment according to:

  • magnitude of weight response,

  • gastrointestinal tolerability,

  • treatment adherence,

  • patient preference,

  • comorbidities,

  • treatment goals, and

  • potentially cost or drug availability.

Horn summarized the potential clinical implication:

โ€œWe have multiple doses that can get patients to double-digit weight loss above 20%.โ€

She further suggested that lower doses might eventually give clinicians and patients additional flexibility when balancing treatment response with tolerability.


CagriSema Remains Investigational

An important distinction is that the efficacy demonstrated in REDEFINE 9 does not itself constitute regulatory approval.

CagriSema remained an investigational product at the time these results were reported.

Therefore, the trial should be interpreted as evidence supporting a potential future therapeutic strategy rather than as an indication to use the combination outside its regulatory status.

Regulatory authorization, approved dosing, contraindications, warnings, and prescribing recommendations will depend on the final decisions of regulatory agencies.


Limitations

1. Relatively Modest Sample Size

REDEFINE 9 randomized 309 participants.

Although adequate to demonstrate efficacy against placebo, this sample is substantially smaller than some large cardiovascular or long-term obesity outcome trials and may not identify uncommon adverse events.

2. Trial Was Not Designed to Compare Active Doses Directly

The close numerical similarity between the 1.0-mg and 1.7-mg groups should not be interpreted as proof of equivalent efficacy.

Each dose was evaluated against placebo.

3. Efficacy Estimand Represents an On-Treatment Scenario

The approximately 21% weight reductions commonly highlighted from REDEFINE 9 are derived from the efficacy estimand.

Treatment-regimen estimand results were slightly smaller, although still clinically substantial.

Both analyses should be considered when interpreting the magnitude of benefit expected in clinical practice.

4. Limited Duration

The principal efficacy endpoint occurred at 68 weeks.

Obesity is a chronic disease that may require treatment over many years, and durability of weight reduction beyond the trial period requires further study.

5. No Participants With Diabetes

Participants with diabetes were excluded.

Therefore, the results should not automatically be extrapolated to individuals with type 2 diabetes.

6. Gastrointestinal Adverse Events

Gastrointestinal adverse effects were the predominant treatment-related concern.

Long-term tolerability will be important if CagriSema is used as chronic therapy.

7. Industry Sponsorship

The study was funded by Novo Nordisk, the manufacturer developing CagriSema.

Several investigators disclosed financial relationships with Novo Nordisk and other pharmaceutical companies.

These disclosures do not invalidate the trial findings but should remain part of critical interpretation of the evidence.


What Doctors Should Know

REDEFINE 9 demonstrates that lower-dose CagriSema regimens can produce large reductions in body weight among adults with obesity or overweight plus obesity-related complications who do not have diabetes.

Clinically important points include:

  • Once-weekly CagriSema 1.7 mg/1.7 mg produced 20.7% mean weight loss under the efficacy estimand.

  • CagriSema 1.0 mg/1.0 mg produced 21.0% mean weight loss.

  • Placebo produced approximately 2.0% weight loss under the same estimand.

  • More than 95% of participants receiving either active dose achieved at least 5% weight loss.

  • Approximately half achieved 20% or greater weight loss.

  • Substantial reductions in waist circumference were also observed.

  • Most adverse events were gastrointestinal and mild to moderate.

  • Treatment discontinuation because of adverse events occurred in fewer than 5% of participants.

  • The similar results with 1.0-mg and 1.7-mg doses do not establish dose equivalence.

  • CagriSema remained investigational at the time of publication.

  • Regulatory approval and eventual approved dosing must be distinguished from trial efficacy.


Bottom Line

In the phase 3b REDEFINE 9 randomized clinical trial, once-weekly CagriSema at doses of 1.7 mg cagrilintide plus 1.7 mg semaglutide and 1.0 mg plus 1.0 mg produced markedly greater weight loss than placebo in adults with obesity or overweight plus at least 1 obesity-related complication and without diabetes.

At 68 weeks, mean weight loss under the efficacy estimand reached 20.7% with the 1.7-mg regimen and 21.0% with the 1.0-mg regimen, compared with 2.0% with placebo.

More than 95% of participants receiving either active dose lost at least 5% of their body weight, and approximately half achieved weight loss of at least 20%.

Adverse events were frequent but predominantly gastrointestinal and mild to moderate, while treatment discontinuation because of adverse events remained uncommon.

The findings provide evidence that substantial weight reduction with CagriSema may be achievable at doses below 2.4 mg of each component, potentially expanding opportunities for individualized dosing.

However, REDEFINE 9 was not powered to establish equivalence between the 1.0-mg and 1.7-mg regimens, and CagriSema remained investigational at the time of publication.


Original Research / DOI

Study: REDEFINE 9

Original article: Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1ยท7 mg each and 1ยท0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial

Journal: The Lancet Diabetes & Endocrinology

Lead author: Sean Wharton and colleagues

Published online: November 14, 2026

DOI: 10.1016/S2213-8587(26)00275-5

PubMed PMID: 43033821

ClinicalTrials.gov identifier: NCT06388187

Funding: Novo Nordisk

The results were also presented at ObesityWeek 2026, November 14-17, 2026, National Harbor, Maryland.

You may also like

Leave a Comment


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?